Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. - Wikidata - wikimedia - TriplyDB

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

http://www.wikidata.org/entity/Q36482760

about

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.Improvement in plasma drug activity during the early treatment interval among Tanzanian patients with multidrug-resistant tuberculosis.Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis Understanding pharmacokinetics to improve tuberculosis treatment outcome.Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory.Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial.Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program.Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands.Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.Management of multidrug-resistant tuberculosis: an update.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium.Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.Antituberculosis drugs in children.Optimizing the clinical pharmacology of tuberculosis medications.Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature.Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers.

P2860

Q24202081-8537BD64-953F-4FD3-B2C3-A9BECEF63E22 Q26775757-FCA7060C-EAA0-46C2-B5F8-360DF583ABB5 Q28543642-19865F5C-27E9-46CF-8F0E-7F072412E4AA Q28545109-549FCDBD-9749-4511-B668-AEA7D76B7A8B Q30411475-0D26337A-5EF4-4E7E-BD46-3E7B2801F311 Q30411703-F593AE43-DC1A-4474-BBAF-BA46897448A9 Q30414792-3FA1EBF0-E63A-4494-B4F6-BC9DC556BA3F Q30415943-926B24EE-9395-4E5F-8BB2-414CFEC2D62E Q33810454-43710BEE-0801-44E0-A4B7-7D7FA6B0CD86 Q35065890-8EC99FA0-A6DF-4225-A906-4C798F548555 Q35197257-63E11E0C-A03D-4502-A959-C066F804397E Q35607890-6956B1AA-1097-478D-A2E6-446615DF4C32 Q35746184-DF5B4D16-853F-44AD-AFA9-7ADF0AABEBE4 Q35800272-8A71BD5A-FDB8-41EF-ABBB-73FC54410663 Q36620922-26DF29D4-B989-4156-A3D5-5482CC02B92B Q36905756-9ED32CCF-FBBA-43D3-A042-5992C306C7A1 Q37032794-7C77C24F-C65F-4C9D-9D85-F37DE3C49026 Q37036499-5B83A2EA-D38B-4902-B683-86A0BB02182B Q37074826-05BB2136-E2B9-44B8-BF24-216AA66360BD Q37120071-F0364780-DF74-48B0-981A-C300A4B907D7 Q37124036-9BA68112-F769-4F64-8124-01141340841E Q37124090-75810CCC-CE8E-4FBC-ACF3-801910CAFA00 Q37218623-8097D349-3695-44BC-B793-7B623B5C9044 Q37346929-21E54D19-C083-4BD2-9489-D03903FD7DA7 Q37392763-96210DF9-9ADD-4EEA-ACA5-34B202012275 Q37426165-5522A556-CEA3-4775-8580-08064AEE2FC3 Q37544479-F463F881-105E-4FC1-9227-708B47327DD8 Q37712966-B8871C0A-A500-4E51-8528-6B8AC08F2F07 Q37730293-1173C3B0-6809-4076-997E-19830BF2C0A1 Q37799461-465F07D0-6C75-4646-828F-A9F86CA2EE11 Q37869912-82B3B521-0286-451E-9146-9B1AE85D66E2 Q38041192-FC2B5FF7-3BE5-4A4E-875A-2D035BB1C521 Q38213320-A5BFE118-F30E-4460-BE38-A1CB7E58B869 Q38445649-3A3386A2-735B-43EC-A42A-E5E8E7BF32A1 Q38488589-E4D111F5-0B6E-4F44-AD49-C010615AF254 Q38533435-7C2DB3A0-21BE-4732-9DB4-844C3A97007F Q38542159-D1D6FC2B-7248-4D36-9919-575247FF43F6 Q38565072-B9F2EC37-F7DB-4953-8B38-B94193955F9C Q38619965-A29A64BD-D986-4009-8E3B-EEEEEEEB9751 Q38676631-0B2E0FD9-297C-4EDE-9AF2-B41FE2FB6056

P2860

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.

http://www.wikidata.org/entity/Q36482760

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Population pharmacokinetics of ...... s with pulmonary tuberculosis.

@ast

Population pharmacokinetics of ...... s with pulmonary tuberculosis.

@en

type

label

Population pharmacokinetics of ...... s with pulmonary tuberculosis.

@ast

Population pharmacokinetics of ...... s with pulmonary tuberculosis.

@en

prefLabel

Population pharmacokinetics of ...... s with pulmonary tuberculosis.

@ast

Population pharmacokinetics of ...... s with pulmonary tuberculosis.

@en

P1433

Q36482760-258EEEAF-E94D-4F66-9C27-3792566C2363

P1476

Q36482760-853CBF7B-97C1-443C-B9A7-17CA4CB3A945

P2093

Q36482760-3A730F20-64FF-4F53-842A-5020CDD2B118

Q36482760-6B060E13-F290-4636-BB06-9CB8F7B4D7FD

Q36482760-7554B1F2-DC77-41BE-B8BA-58C28AF844B2

Q36482760-7B81B6CE-6A31-4369-94F7-7A39350DF75C

Q36482760-F60BF478-52F1-4CFB-9099-473DC5DE9137

Q36482760-F781E21B-CB40-4B54-AA2A-0AA702BAE334

Q36482760-FB7E96CA-3DA8-4595-9C73-8C2F4A6C206F

P2860

Q36482760-05ACEE23-B404-4591-B040-8C8E09500A12

Q36482760-1AAA59E4-3BAF-473A-8785-40F86EAB919C

Q36482760-1D01949E-1B56-4A02-AD9D-EC68CA757674

Q36482760-3E1DA21E-3EA1-4063-8990-2449FFE13CF4

Q36482760-3F4619DA-3FC9-4282-9CE8-0D8D6EC8CC64

Q36482760-51C1CCDB-0DD1-4AEB-8D5A-9730E426B164

Q36482760-66773DF9-61C4-4E85-85AB-C1462B1F27A6

Q36482760-6859435D-2F9D-40B2-B412-9C7762896956

Q36482760-797B7446-EB43-4B5E-BE3D-698290C4E328

Q36482760-9B51E659-956A-4244-BCA6-C1CF8C554DBE

P304

Q36482760-207B252D-1AA4-4532-B1FB-047FA17340F5

P31

Q36482760-442AEF63-892C-4F2E-B7A7-2BD3CE269E4F

P356

Q36482760-6AD97F49-17CE-422E-9993-C2BF56A50B1E

P407

Q36482760-69A31D74-5D83-4C7B-A15C-835726092798

P433

Q36482760-2780AE9B-75E9-4E71-AD47-86164C70095C

P478

Q36482760-7A769A6A-87CB-486D-9D3D-CC8779792B50

P577

Q36482760-136FB318-B1E3-4E08-AB58-061B4D9A393A

P5875

Q36482760-218EE587-4ED6-46AB-B55B-D9E6210D625B

P698

Q36482760-9A6B4C09-41CA-4AC1-81AB-856DDFDB28FC

P921

Q36482760-29F8D945-8288-4C6C-9550-CC25D7704F49

P932

Q36482760-962CB822-487A-4AB5-872F-8518864AD0FC

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Population pharmacokinetics of ...... s with pulmonary tuberculosis.

@en

P2093

Charles A Peloquin

http://www.w3.org/2001/XMLSchema#string

David Jamil Hadad

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Lucilia Pereira Dutra Molino

http://www.w3.org/2001/XMLSchema#string

Moises Palaci

http://www.w3.org/2001/XMLSchema#string

Reynaldo Dietze

http://www.w3.org/2001/XMLSchema#string

W Henry Boom

http://www.w3.org/2001/XMLSchema#string

P2860

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Prediction of creatinine clearance from serum creatinine

Therapeutic drug monitoring in the treatment of tuberculosis.

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.

Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin

Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.

Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.

Ofloxacin population pharmacokinetics in patients with tuberculosis.

Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.

P304

852-857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01036-07

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5777364

http://www.w3.org/2001/XMLSchema#string

P698

18070980

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

2258503

http://www.w3.org/2001/XMLSchema#string